Incretin-based therapies: viewpoints on the way to consensus.
2009; National Institutes of Health; Volume: 32 Suppl 2; Linguagem: Inglês
10.2337/dc09-s315
AutoresMichael A. Nauck, Tina Vilsbøll, Baptist Gallwitz, Alan J. Garber, Sten Madsbad,
Tópico(s)Diabetes Management and Research
ResumoIncretin mimetics and inhibitors of the protease dipeptidyl peptidase (DPP)-4 are new classes of antidiabetic agents first introduced in the years 2005 (exenatide) and 2007 (sitagliptin), respectively. Both use the antidiabetic properties of the incretin hormone, glucagon-like peptide (GLP)-1 (1). This gut-derived peptide hormone not only augments glucose-induced insulin secretion (required to fulfill the definition of an incretin hormone), but does so in a highly glucose-dependent manner (2), thus preventing GLP-1 alone from provoking hypoglycemia. Additional beneficial effects of GLP-1 on endocrine pancreatic islets are that it 1 ) supports the synthesis of proinsulin to replenish insulin stores in β-cells; 2 ) reduces the rate of β-cell apoptosis when islets are incubated in a toxic environment (glucotoxicity, lipotoxicity, cytotoxic cytokines); and 3 ) promotes differentiation of precursor cells with the ability to develop into β-cells and proliferation of β-cell lines, and in whole animals (rodent studies), this leads to an increased β-cell mass within a few days or weeks (1,3). Furthermore, GLP-1 can lower glucagon concentrations, i.e., induce α-cells to respond again to the inhibitory action of hyperglycemia, while leaving the counterregulatory glucagon responses undisturbed, as in the case of hypoglycemia (2,4). Additional activities of GLP-1 are the deceleration of gastric emptying (5), which slows the entry of nutrients into the circulation after meals, a reduction in appetite, and earlier induction of satiety (6), leading to weight reduction with chronic exposure (7). Renal effects (promotion of sodium and water excretion (8), as well as neuro- (9) and cardioprotective (10) properties of GLP-1, have also been described. While GLP-1 is perfectly suitable for lowering, or even stabilizing, glucose concentrations in short-term experiments, its short half-life (∼1–2 min for the intact, biologically active form) caused by rapid proteolytic degradation and inactivation through the ubiquitous enzyme DPP-4 and renal elimination (Fig. 1 …
Referência(s)